bcbs semaglutide coverage Blue Cross Blue Shield of Michigan won't cover popular weight-loss drugs Blue Cross Blue Shield

Alford, T.J

Restrain/Challenge High Development Costs and Regulatory Complexities The main challenge that oral non-peptide GLP-1 receptor agonists will face in this market would be the difficulty in developing highly efficacious formulations that are able to offer similar therapeutic benefits to those offered by injectables

Individuals with estimated glomerular filtration rate below 30 mL per min should use tirzepatide with caution, starting at 2.5 mg and escalating more slowly while monitoring renal function closely

These findings demonstrate that the metabolic benefits of tirzepatide beyond calorie restriction are real and significant